Plasminogen activator inhibitor I (PAI-1) 1334G/A genetic polymorphism in colorectal cancer

Acta Biochimica Polonica

Volumn 50, Issue 2, 2003, Pages 489-495

  Smolarz, Beata ^a   Romanowicz Makowska, Hanna ^a   Kulig, Andrzej ^a  

^a POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

Author keywords

1334G A polymorphism; Colorectal cancer; PCR; Plasminogen activator inhibitor 1 (PAI 1); Prognostic marker

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; ALLELE; ARTICLE; BLOOD SAMPLING; CANCER TISSUE; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; HYPOTHESIS; INCIDENCE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION;

EID: 0042381668     PISSN: 0001527X     EISSN: None     Source Type: Journal    
DOI: 10.18388/abp.2003_3701     Document Type: Article

References (33)

1. Abe J, Urano T, Konno H, Erhan Y, Tanaka T, Nishino N, Tahada A, Nakamura S. (1999) Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size. Cancer.; 86: 2602-11.
2. Błasiak J, Smolarz B. (2000) Plasminogen activator inhibitor 1 (PAI-1) gene 4G/5G promoter polymorphism is not associated with breast cancer. Acta Biochim Polon.; 47: 191-9.
3. Błasiak J, Smolarz B, Kubryn I, Kulig A, Dziki A, Ulańska J, Pander B. (2000) Plasminogen activator inhibitor-1 (PAI-1) level and 4G/5G genetic polymorphism in patients with colorectal cancer. Exp Oncol.; 22: 48-51.
4. Błasiak J, Smolarz B, Romanowicz-Makowska H, Pertyński T. (2000) Polymorphisms of the promoter region of the plasminogen activator-1 (PAI-1) gene in women with endometrial cancer. Pol J Gynaecol Invest.; 3: 61-6.
5. Bosma PJ, van den Berg EA, Kooistra T, Siemieniak DR, Slightom JL. (1988) Human plasminogen activator inhibitor 1 gene promoter and structural gene nucleotide sequences. J Biol Chem.; 263: 9129-41.
6. Burzotta F, Di Castelnuovo A, Amore C, D'Orazio A, Di Bitondo R, Donati MB, Iacoviello L. (1998) 4G/5G promoter PAI-1 gene polymorphism is associated with plasmatic PAI-1 activity in Italians: a model of gene-enviroment interaction. Thromb Haemost.; 79: 354-8.
7. Carroll VA, Binder BR. (1999) The role of the plasminogen activation system in cancer. Seminars Thromb Haemost.; 25: 183-97.
8. Dano K, Romer J, Nielsen BS, Bjorn S, Pyke C, Rygaard J, Lund R. (1999) Cancer invasion and tissue remodeling - cooperation of protease systems and cell types. APMIS.; 107: 120-7.
9. Eliasson B, Attval S, Taskinen MR, Smith U. (1994) The insulin resistance syndrome in smokers is related to smoking habits. Arterioscler Thromb.; 14: 1446-50.
10. Eriksson P, Kallin B, van Hooft FM, Bavenholm P, Hamsten A. (1995) Allele-specific increase in basal transcription of the plasminogen activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A.; 92: 1851-5.
11. Eriksson P, Kallin B, Van't Hooft FM, Bavenholm P, Hamsten A. (1995) Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A.; 92: 1851-5.
12. Falk G, Sui GC, Schulman S, Wiman B. (1999) Detection of a new polymorphism in the PAI-1 gene located in the pro-peptide coding region. Fibrinolysis Proteolysis.; 13: 26-30.
13. Fuji T, Obara T, Tanno S, Ura H, Kohgo Y. (1999) Urokinase type plasminogen activator and plasminogen activator inhibitor 1 as a prognostic factor in human colorectal carcinomas. Hepatogastroenterology.; 28: 2299-308.
14. Grancha S, Estelles A, Tormo G, Gilabert J, Espana F, Cano A, Segui R, Aznar J. (1999) Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease. Thromb Haemost.; 81: 516-21.
15. Green F, Humphries SE. (1994) Genetic determinants of arterial thrombosis. Balliers Clin Haematol.; 7: 675-93.
16. Hendriks HFJ, Veenstgra J, Velthuiste Wierik EJM Schaafsma G, Kluft C. (1994) Effect of moderate dose of alcohol with evening meal on fibrinolytic factors. Br Med J.; 308: 1003-5.
17. Henry M, Chomiki N, Scarabin PY, Alessi MC, Peiretti F, Arveiler D, Ferrieres J, Evans A, Amouyel P, Poirier O, Cambien F, Juhan-Vague I. (1997) Five frequent polymorphisms of the PAI-1 gene. Arterioscler Thromb Vasc Biol.; 17: 851-8.
18. Henry M, Tregoue DA, Alessi MC, Ailland MF, Visvikis S, Siest G, Tiret L, Juhan-Vague I. (1998) Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concetrations: a family study with part of the Stanislas Cohort. Arterioscler Thromb Vasc Biol.; 18: 84-91.
19. Herszenyi C, Plebani M, Carrano P, De Paoli M, Roveroni G, Cardin R, Tulessay Z, Naccarato R, Forinati F. (1999) The role of cysteine and serine proteases in colorectal carcinoma. Cancer.; 86: 1135-42.
20. Kerins DM, Hao Q, Vaughan DE. (1995) Angiotensin induction of PAI-1 in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest. ; 96: 2515-20.
21. Lijnen HR. (2001) Elements of the fibrinolytic system. Ann N Y Acad Sci U S A.; 936: 226-36.
22. Mansfield MW, Stickland MH, Grant PJ. (1995) Plasminogen activator inhibitor-1. (PAI-1) promoter polymorphism and coronary artery disease in non-insulin dependent diabetes. Thromb Haemost.; 74: 1032-4.
23. Meyer T, Hart IR. (1998) Mechanisms of tumour metastasis. Eur J Cancer.; 34: 214-21.
24. Nielsen HJ, Pappot H, Christensen IJ, Brunner N, Thorlacius-Ussing O, Moesgaard F, Dano K, Grondahl-Hansen J. (1998) Association between plasma concetrations of plasminogen activator inhibitor 1 and survival in patients with colorectal cancer. Br Med J.; 316: 829-30.
25. Pralong G, Calandra T, Glauser MP, Schellekens J, Verhoef J, Bachmann F, Kruithof EKO. (1989) Plasminogen activator inhibitor 1: a new prognostic marker in septic shock. Thromb Haemost.; 61: 459-62.
26. Sattar N, McMillan DC. (1998) Association between plasma plasminogen activator inhibitor 1 and survival in colorectal cancer measuring C reactive protein concetrations may be more useful. British Medical J.; 317: 750-1.
27. Schmitt M, Harbeck N, Thomssen C, Wilhelm O, Magdolen V, Reuning U, Ulm K, Hofler H, Janicke F, Graeff H. (1997) Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost.; 78: 285-96.
28. Smolarz B, Błasiak J. (1999) Plasminogen activator inhibitor-1 promoter 4G/5G genotype in subjects with breast cancer. Biom Lett.; 60: 97-105.
29. Smolarz B, Błasiak J, Kulig A, Romanowicz-Makowska H, Dziki A, Ulańska J, Pander B, Szewczyk T. (2001) Plasminogen activator inhibitor 1 (PAI-1) levels and gene promoter polymorphism in subjects with colorectal cancer. J Exp Clin Cancer Res.; 20: 247-52.
30. Stegnar M, Uhrin P, Peternel P, Mavri A, Salobir-Pajnic B, Stare J, Binder BR. (1998) The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism. Thromb Haemost.; 79: 975-9.
31. Weiss AA, Itzkowitz SH. (1995) Biology diagnosis and therapy. In Gastrointestinal Cancers. pp 353-65. Lippincott-Raven, Philadelphia.
32. Yang XC, Jing TY, Resnick LM, Phillips GB. (1993) Relation of hemostatic risk factors to other risk factors for coronary heart disease and to sex hormone in men. Arterioscler Thromb.; 13: 467-71.
33. Ye S, Green FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ, Humphries SE, Evans A, Luc G, Cambau JP, Arveiler D, Henney AM, Cambien F. (1995) The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with difference in plasma PAI-1 activity but not risk factor of myocardial infarction in the ECTIM study. Thromb Haemost.; 74: 837-41.